Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
25.94
-0.74 (-2.77%)
Feb 11, 2026, 4:00 PM EST - Market closed
Immunovant Stock Forecast
Stock Price Forecast
The 9 analysts that cover Immunovant stock have a consensus rating of "Buy" and an average price target of $30.78, which forecasts a 18.66% increase in the stock price over the next year. The lowest target is $17 and the highest is $50.
Price Target: $30.78 (+18.66%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immunovant stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 4 | 4 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +34.93% | Feb 10, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $41 → $44 | Strong Buy | Maintains | $41 → $44 | +69.62% | Feb 9, 2026 |
| Truist Securities | Truist Securities | Hold Maintains $16 → $22 | Hold | Maintains | $16 → $22 | -15.19% | Jan 8, 2026 |
| Wolfe Research | Wolfe Research | Hold → Buy Upgrades $50 | Hold → Buy | Upgrades | $50 | +92.75% | Jan 6, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $18 → $28 | Hold | Maintains | $18 → $28 | +7.94% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
23.04M
EPS This Year
-2.97
from -2.73
EPS Next Year
-3.00
from -2.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 90.7M | |||
| Avg | n/a | 23.0M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.67 | -2.06 | |||
| Avg | -2.97 | -3.00 | |||
| Low | -3.15 | -3.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.